Community practices not following guidelines for MRI breast cancer screening
Study finds at-risk groups of women in the US are not receiving MRI scans, whereas lower risk groups are being scanned too often
Heidelberg | New York, 7 December 2017
Guidelines are not being followed to ensure that breast cancer screening of high risk women, such as those with a strong family history of breast cancer, includes an additional MRI (magnetic resonance imaging) scan. According to Deirdre A. Hill of the University of New Mexico School of Medicine in the US, this signals a missed opportunity to use technology that can help detect breast cancer early in high-risk groups. She led a study in the Journal of General Internal Medicine which is published by Springer.
Since the first guidelines were issued in 2007, MRI is increasingly used to further screen for the signs of breast cancer after mammography. The American Cancer Society, the American College of Radiology and the Society of Breast Imaging all recommend these to women who have a 20 percent or more chance of contracting the disease. The use of MRI scans for women in this high-risk group has led to better detection rates compared to when mammograms are used alone.
Data were analyzed from the Breast Cancer Surveillance Consortium (BCSC), a breast imaging network that collects information on risk factors, imaging and, cancer diagnoses including pathology of women who are screened. Among the 348,955 women in five regional BCSC regional registries who received mammograms, 1499 also underwent MRI scanning. Hill’s team considered the chances of a woman receiving MRIs together with factors such as her family history of breast cancer and other breast cancer risk factors.
The study’s findings show that screening MRI in community settings is not used according to current professional guidelines. Approximately 82,9 percent of screening MRIs were done on women who did not meet the professional guidelines. Of these women, 35,5 percent fell in the low to average risk group. In contrast, only a fraction of the women who met professional guidelines for additional screening MRI received this service.
“Our data suggest that women with less than 20 percent lifetime risk based on family history, but who have high breast density, breast atypia, or abnormal cell growth called lobular carcinoma in situ undergo MRI at many times the rate of other women, although the harms and benefits in this population are uncertain and the cost-benefit ratio may exceed established benchmarks,” Hill explains. “Such women may not be at substantially increased risk of cancers missed by mammography and thus may not be the groups in greatest need or who would receive the greatest potential benefit of screening MRI.”
“Breast MRI use that is not concordant with guidelines, as documented in this study, poses distinct challenges to effective resource allocation in breast cancer screening,” Hill adds.
Reference: Hill, D.A. et al (2017). Utilization of Breast Cancer Screening with Magnetic Resonance Imaging in Community Practice Journal of General Internal Medicine DOI: 10.1007/s11606-017-4224-6
Further Information
The Journal of General Internal Medicine is the official journal of the Society of General Internal Medicine
In a related article in the Journal of General Internal Medicine using the Surveillance, Epidemiology, and End Results (SEER) registry, nine percent of women with advanced colon or lung cancer and a mean age of 75 underwent screening mammography despite a predicted five year survival rate of <20 percent from their already known cancer. Eleven percent of these screening mammograms prompted additional testing resulting in added costs and probable anxiety with little likelihood of benefit.
Reference: Sadigh G. et al (2017) Downstream Breast Imaging following Screening Mammography in Medicare Patients with Advanced Cancer: A Population-based Study Journal of General Internal Medicine DOI: 10.1007/s11606-017-4212-x
Services for Journalists
The full-text article is available to journalists on request.
Contact
Elizabeth Hawkins | Springer Nature | Communications
tel +49 6221 487 8130 | elizabeth.hawkins@springer.com